Processa Pharmaceuticals, Inc. (PCSA)

Processa Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	5	8	18	77	70	70
Market Cap Growth	-45.00%	-53.15%	-77.16%	10.52%	-0.39%	-49.76%
Enterprise Value	-4	4	11	61	55	70
PE Ratio	-	-0.74	-0.64	-6.74	-4.83	-20.83
PB Ratio	0.52	1.65	2.36	3.02	3.04	8.73
P/FCF Ratio	-0.84	-1.02	-1.83	-8.83	-22.17	-25.44
P/OCF Ratio	-0.84	-1.02	-1.83	-8.83	-22.17	-25.44
EV/EBITDA Ratio	0.21	-0.33	-0.43	-5.47	-3.83	-23.08
EV/EBIT Ratio	0.21	-0.33	-0.41	-5.07	-3.61	-17.91
EV/FCF Ratio	0.25	-0.46	-1.18	-6.95	-17.37	-25.56
Debt / Equity Ratio	0.02	0.03	0.03	0.00	0.01	0.13
Debt / EBITDA Ratio	-0.01	-0.01	-0.01	-0.01	-0.02	-0.34
Debt / FCF Ratio	-0.02	-0.02	-0.02	-0.01	-0.10	-0.37
Quick Ratio	8.85	6.44	6.51	16.99	12.75	0.58
Current Ratio	9.70	7.71	8.40	18.87	13.27	0.85
Interest Coverage	-	-	-	-	-53.83	-107.04
Return on Equity (ROE)	-130.10%	-141.40%	-161.20%	-40.40%	-136.30%	-39.10%
Return on Assets (ROA)	-115.90%	-122.20%	-149.90%	-38.10%	-105.20%	-29.80%
Return on Capital (ROIC)	-110.55%	-222.91%	-357.46%	-47.46%	-65.06%	-43.53%
Earnings Yield	-210.92%	-134.94%	-155.91%	-14.84%	-20.69%	-4.80%
FCF Yield	-171.69%	-97.87%	-54.61%	-11.32%	-4.51%	-3.93%
Buyback Yield / Dilution	-116.63%	-62.83%	-5.16%	-104.27%	-35.72%	-3.63%
Total Shareholder Return	-116.63%	-62.83%	-5.16%	-104.27%	-35.72%	-3.63%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).